Endothelial dysfunction

Source: Wikipedia, the free encyclopedia.
Comparison of healthy vs. dysfunctional vascular endothelium

In

vascular tone and regulating oxidative stress by releasing mediators, such as nitric oxide, prostacyclin and endothelin, and by controlling local angiotensin-II activity.[1][2]

Dysfunctional endothelium is characterized by vasoconstriction, increased vascular permeability, thrombosis, and inflammation. This pathological state is often associated with elevated levels of biomarkers such as prothrombin time, D-dimer, fibrin degradation products, C-reactive protein (CRP), ferritin, Interleukin 6 (IL-6), and plasma creatinine. The result of this endothelial dysregulation is a cascade of adverse effects, including vasoconstriction, vascular leakage, thrombosis, hyperinflammation, and a disrupted antiviral immune response. These changes contribute to the progression of vascular diseases.[3]

In a healthy state, the endothelium exhibits vasodilation, tightly controlled vascular permeability, and anti-thrombotic and anti-inflammatory properties. This balance ensures the smooth functioning of the vascular system.[3]

Research

Atherosclerosis

Stages of endothelial dysfunction in atherosclerosis of arteries

Endothelial dysfunction may be involved in the development of atherosclerosis[4][5][6] and may predate vascular pathology.[4][7] Endothelial dysfunction may also lead to increased adherence of monocytes and macrophages, as well as promoting infiltration of low-density lipoprotein (LDL) in the vessel wall.[8] Dyslipidemia and hypertension are well known to contribute to endothelial dysfunction,[9][10] and lowering blood pressure and LDL has been shown to improve endothelial function, particularly when lowered with ACE inhibitors, calcium channel blockers, and statins.[11]

Nitric oxide

Nitric oxide (NO) suppresses platelet aggregation, inflammation, oxidative stress, vascular smooth muscle cell migration and proliferation, and leukocyte adhesion.

nitroglycerine,[4] that stimulates release of vasodilators from the endothelium like NO. Endothelial dysfunction is commonly associated with decreased NO bioavailability, which is due to impaired NO production by the endothelium or inactivation of NO by reactive oxygen species.[citation needed
]

Testing and diagnosis

In the

ultrasonography are used to assess endothelial function of peripheral vessels in humans.[4]

A

non-invasive method to measure endothelial dysfunction is % Flow-Mediated Dilation (FMD) as measured by Brachial Artery Ultrasound Imaging (BAUI).[12] Current measurements of endothelial function via FMD vary due to technical and physiological factors. Furthermore, a negative correlation between percent flow mediated dilation and baseline artery size is recognised as a fundamental scaling problem, leading to biased estimates of endothelial function.[13]

A non-invasive, FDA-approved device for measuring endothelial function that works by measuring Reactive Hyperemia Index (RHI) is Itamar Medical’s EndoPAT.[14][15] It has shown an 80% sensitivity and 86% specificity to diagnose coronary artery disease when compared against the gold standard, acetylcholine angiogram.[16] This results suggests that this peripheral test reflects the physiology of the coronary endothelium.

Since NO maintains low tone and high compliance of the small arteries at rest,[17] a reduction of age-dependent small artery compliance is a marker for endothelial dysfunction that is associated with both functional and structural changes in the microcirculation.[18] Small artery compliance or stiffness can be assessed simply and at rest and can be distinguished from large artery stiffness by use of pulsewave analysis.[19]

Endothelial dysfunction and stents

Stent implantation has been correlated with impaired endothelial function in several studies.[20] Sirolimus eluting stents were previously used because they showed low rates of in-stent restenosis, but further investigation showed that they often impair endothelial function in humans and worsen conditions.[20] One drug used to inhibit restenosis is iopromide-paclitaxel.[21]

Risk reduction

Treatment of

angiotensin II receptor antagonists.[22][23] Calcium channel blockers and selective beta 1 antagonists may also improve endothelial dysfunction.[11] Life style modifications such as smoking cessation have also been shown to improve endothelial function and lower the risk of major cardiovascular events.[24]

See also

References

  1. PMID 20678595
    .
  2. PMID 22869857
    .
  3. ^
    PMID 33375371
    .
  4. ^
    S2CID 4948849
    .
  5. ^
    PMID 24222847
    .
  6. PMID 35002720
    .
  7. S2CID 18542183
    .
  8. S2CID 71334997
    .
  9. PMID 30674709
    .
  10. PMID 28035582
    .
  11. ^
    PMID 22112351
    .
  12. PMID 17376239
    .
  13. PMID 20952670
    .
  14. PMID 17451088
    .
  15. PMID 20972417
    .
  16. PMID 15582310
    .
  17. PMID 20409832
    .
  18. PMID 21709134
    .
  19. PMID 19886784
    .
  20. ^
    PMID 28989698
    .
  21. PMID 19487593
    .
  22. PMID 17583170
    .
  23. PMID 22280336
    .
  24. PMID 24554606
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Endothelial_dysfunction&oldid=1219625735"